SCHEMBL15215172

SCHEMBL15215172

COc1ccc(CN(C(=O)OCc2ccccc2)[C@@H](C)CO)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ACHE P22303 2/20 0.48
▸ TSHR P16473 2/20 0.46
▸ ATM Q13315 2/20 0.46
▸ ALDH1A1 P00352 1/20 0.46
▸ LMNA P02545 1/20 0.46
▸ POLB P06746 1/20 0.46
▸ HSD17B10 Q99714 1/20 0.46
▸ L3MBTL1 Q9Y468 1/20 0.46
▸ TDP1 Q9NUW8 2/20 0.45
▸ CA1 P00915 1/20 0.45
▸ CA2 P00918 1/20 0.45
▸ MAPK1 P28482 1/20 0.44
▸ PSEN1 P49768 1/20 0.44
▸ PSEN2 P49810 1/20 0.44
▸ APH1B Q8WW43 1/20 0.44
▸ NCSTN Q92542 1/20 0.44
▸ APH1A Q96BI3 1/20 0.44
▸ PSENEN Q9NZ42 1/20 0.44
▸ FABP7 O15540 1/20 0.44
▸ FABP5 Q01469 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15209538 0.86 ATM (0.50) ACHETSHRATMALDH1A1LMNA
SCHEMBL15209541 0.86 ATM (0.50) ACHETSHRATMALDH1A1LMNA
SCHEMBL15215174 0.84 ACHE (0.47) ACHETSHRATMALDH1A1LMNA
SCHEMBL15211141 0.84 ACHE (0.47) ACHETSHRATMALDH1A1LMNA
SCHEMBL15209900 0.83 LDHA (0.50) ACHETSHRALDH1A1TDP1MAPK1
SCHEMBL15215173 0.80 ACHE (0.43) ACHETSHRATMALDH1A1LMNA
SCHEMBL13342957 0.79 CTSL (0.44) ACHETSHRATMALDH1A1LMNA
SCHEMBL15215178 0.79 TSHR (0.43) ACHETSHRATMALDH1A1LMNA
SCHEMBL18220636 0.78 ALDH1A1 (0.49) ATMALDH1A1LMNAPOLBHSD17B10
SCHEMBL7720033 0.77 ALDH1A1 (0.50) ALDH1A1LMNAPOLBHSD17B10L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9458177-B2 Oxazolidin-2-one compounds and uses thereof NOVARTIS AG (CH) 2016-10-04 — — US disclosed
US-9458177-B2 Oxazolidin-2-one compounds and uses thereof NOVARTIS AG (CH) 2016-10-04 — — US disclosed
EP-2817307-B1 OXAZOLIDIN-2-ONE COMPOUNDS AND USES THEREOF AS PI3KS INHIBITORS NOVARTIS AG (CH) 2016-07-13 — — EP disclosed
US-20140378450-A1 OXAZOLIDIN-2-ONE COMPOUNDS AND USES THEREOF NOVARTIS AG (CH) 2014-12-25 — — US disclosed
US-20140378450-A1 OXAZOLIDIN-2-ONE COMPOUNDS AND USES THEREOF NOVARTIS AG (CH) 2014-12-25 — — US disclosed
US-8865894-B2 Oxazolidin-2-one compounds and uses thereof NOVARTIS AG (CH) 2014-10-21 — — US disclosed
US-8865894-B2 Oxazolidin-2-one compounds and uses thereof NOVARTIS AG (CH) 2014-10-21 — — US disclosed
WO-2013124826-A1 OXAZOLIDIN- 2 -ONE COMPOUNDS AND USES THEREOF AS PI3KS INHIBITORS NOVARTIS AG (CH) 2013-08-29 — — WO disclosed
US-20130225574-A1 OXAZOLIDIN-2-ONE COMPOUNDS AND USES THEREOF NOVARTIS AG (CH) 2013-08-29 — — US disclosed
US-20130225574-A1 OXAZOLIDIN-2-ONE COMPOUNDS AND USES THEREOF NOVARTIS AG (CH) 2013-08-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140378450-A1 OXAZOLIDIN-2-ONE COMPOUNDS AND USES THEREOF PIK3CA, PIK3CD, PIK3CB ACHE 4377/4885TSHR 3875/4885ATM 394/4885
US-20130225574-A1 OXAZOLIDIN-2-ONE COMPOUNDS AND USES THEREOF PIK3CA, PIK3CD, PIK3CB ACHE 4377/4885TSHR 3875/4885ATM 394/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback